Update on allergy immunotherapy:AAAAI & EAACI PRACTALL consensus report

Update on allergy immunotherapy:AAAAI & EAACI PRACTALL consensus report

Allergy immunotherapy (AIT) is an effective treatment forallergic asthma and rhinitis, as well as venom-inducedanaphylaxis. In addition to reducing symptoms, AIT can changethe course of allergic disease and induce allergen-specificimmune tolerance. In current clinical practice immunotherapyis delivered either subcutaneously or sublingually; someallergens, such as grass pollen, can be delivered through eitherroute, whereas others, such as venoms, are only deliveredsubcutaneously. Both subcutaneous and sublingualimmunotherapy appear to have a duration of efficacy of up to 12years, and both can prevent the development of asthma and newallergen sensitivities. In spite of the advances with AIT, saferand more effective AIT strategies are needed, especially forpatients with asthma, atopic dermatitis, or food allergy. Novelapproaches to improve AIT include use of adjuvants orrecombinant allergens and alternate routes of administration.As part of the PRACTALL initiatives, the European Academyof Allergy and Clinical Immunology and the AmericanAcademy of Allergy, Asthma & Immunology nominated anexpert team to develop a comprehensive consensus report on themechanisms of AIT and its use in clinical practice, as well asunmet needs and ongoing developments in AIT. This resultingreport is endorsed by both academies.